Publications:

CRISPR-Cas9 screen reveals a role of purine synthesis for estrogen receptor α activity and tamoxifen resistance of breast cancer cells.

Science Advances

Hany, Dina D; Vafeiadou, Vasiliki V; Picard, Didier D

Publication Date: 2023-05-12

Variant appearance in text: ESR1: S305A

PubMed Link: 37172090

Variant Present in the following documents:

• Main text
• sciadv.add3685.pdf

View BVdb publication page

Structural and Molecular Mechanisms of Cytokine-Mediated Endocrine Resistance in Human Breast Cancer Cells.

Molecular Cell

Stender, Joshua D JD; Nwachukwu, Jerome C JC; Kastrati, Irida I; Kim, Yohan Y; Strid, Tobias T; Yakir, Maayan M; Srinivasan, Sathish S; Nowak, Jason J; Izard, Tina T; Rangarajan, Erumbi S ES; Carlson, Kathryn E KE; Katzenellenbogen, John A JA; Yao, Xin-Qiu XQ; Grant, Barry J BJ; Leong, Hon S HS; Lin, Chin-Yo CY; Frasor, Jonna J; Nettles, Kendall W KW; Glass, Christopher K CK

Publication Date: 2017-03-16

Variant appearance in text: ESR1: S305A

PubMed Link: 28306507

Variant Present in the following documents:

• Main text

View BVdb publication page

p21-activated kinase group II small compound inhibitor GNE-2861 perturbs estrogen receptor alpha signaling and restores tamoxifen-sensitivity in breast cancer cells.

Oncotarget

Zhuang, Ting T; Zhu, Jian J; Li, Zhilun Z; Lorent, Julie J; Zhao, Chunyan C; Dahlman-Wright, Karin K; Strömblad, Staffan S

Publication Date: 2015-12-22

Variant appearance in text: ESR1: S305A

PubMed Link: 26554417

Variant Present in the following documents:

• Main text
• oncotarget-06-43853.pdf

View BVdb publication page